About Lexaria Bioscience Corp. - Common Stock (LEXX)
Lexaria Bioscience Corp is a biotechnology company that focuses on the development of its proprietary drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients. The company's primary goal is to improve the efficacy and speed of absorption for various compounds, particularly those related to cannabis and nicotine. Through its innovative methods, Lexaria aims to revolutionize the way these substances are consumed, potentially leading to more effective therapeutic outcomes and improved user experiences in the market for both recreational and medicinal products. Read More
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow traded up 0.83% to 46,328.48 while the NASDAQ rose 0.45% to 22,484.92. The S&P 500 also rose, gaining, 0.62% to 6,645.73.
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Friday. The Dow traded up 0.58% to 46,213.26 while the NASDAQ rose 0.31% to 22,455.17. The S&P 500 also rose, gaining, 0.47% to 6,636.07.
KELOWNA, BC / ACCESS Newswire / September 26, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,666,667 shares of common stock. The warrants will have an exercise price of $1.37 per share, will be immediately exercisable and will expire five years from the date of the effectiveness of the resale registration statement registering the shares of common stock issuable upon exercise of the unregistered warrants. The closing of the offering is expected to occur on or about September 29, 2025, subject to the satisfaction of customary closing conditions.
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.
Lexaria Bioscience Corp. (NASDAQ: LEXX) experienced a dramatic 45.10% surge in after-hours trading on Thursday, climbing to $2.22 from its closing price of $1.53.
KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025.
KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the important study milestone known as last patent last visit ("LPLV") in Lexaria's Phase 1b glucagon-like peptide-1 ("GLP-1") study in Australia, GLP-1-H24-4 (the "Study").
KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments.
KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.00 per share (or per pre-funded warrant in lieu thereof) Other than the pre-funded warrants, no other warrants were issued to the institutional investor in the registered direct offering.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
